The mechanism of action of durvalumab involves its role as an immune checkpoint inhibitor. Cancer cells often express PD-L1 as a means to evade detection by the immune system. Durvalumab binds to PD-L1, preventing it from interacting with PD-1 receptors on T-cells. This unleashes the immune response, allowing T-cells to recognize and kill cancer cells more effectively.
